The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Whyte, N Engl J Med 354(8):860-863 February 23, 2006.

Correction
PreviousPrevious
Volume 355:638 August 10, 2006 Number 6
NextNext

The Long and Short of Bone Therapy

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Whyte, M. P.
The Long and Short of Bone Therapy . On page 860, the sentence that begins on line 3 of the second paragraph should have read, "In this issue of the Journal, from a study that was sponsored, designed, and analyzed by Amgen, McClung et al.3 report on the safety and efficacy of various doses of denosumab (formerly known as AMG 162), a fully human monoclonal antibody to the receptor activator of nuclear factor-{kappa}B (RANK) ligand (RANKL)," not "a humanized monoclonal antibody," as printed.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.